ORBIMED ADVISORS LLC — 13F Holdings & Portfolio
CIK 1055951 · latest 13F-HR filed 2026-08-14
ORBIMED ADVISORS LLC manages $5.40B in 13F-reported U.S. long-equity assets across 129 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are EWTX (11.68%), ELVN (6.37%), LLY (5.73%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 35 new positions and exited 21; 52 existing positions rose in reported value and 22 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 43%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Aug 18, 2026.
54TH FLOOR
NEW YORK, NY 10022
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| ASHIYA, MONA Control | MEMBER since Jul 2025 | 5–10% | Individual |
| BLOCK III, SAM Control | CHIEF FINANCIAL OFFICER since May 2019 | Less than 5% | Individual |
| BONITA, DAVID, PAUL Control | MEMBER since Jan 2020 | 5–10% | Individual |
| COON, DOUGLAS, W. Control | CHIEF COMPLIANCE OFFICER since Feb 2016 | Less than 5% | Individual |
| COOPER, ALEXANDER, MATTHEW Control | GENERAL COUNSEL since Jul 2010 | Less than 5% | Individual |
| GORDON, CARL, LEE Control | MEMBER since Jan 1998 | 25–50% | Individual |
| HSU, GEOFFREY, CHE-CHANG Control | MEMBER since Jan 2010 | 10–25% | Individual |
| NEILD, WILLIAM, CARTER Control | MEMBER since Jan 2007 | 10–25% | Individual |
| Rizzo, Matthew, Scott Control | MEMBER since Jan 2022 | 5–10% | Individual |
| STEVENS, CHARLES, SCOTLAND Control | MEMBER since Apr 2019 | 5–10% | Individual |
| Thompson, Peter, Armstrong Control | MEMBER since Jan 2022 | 5–10% | Individual |
Ownership & leadership changes · 9 filings with changes since Mar 7, 2012
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- No longer listedBORHO, SVEN, HEINZ · MEMBER · 25–50% · control person · listed since Jan 1998
- ChangedASHIYA, MONA · ownership Less than 5% → 5–10%
- ChangedBONITA, DAVID, PAUL · ownership Less than 5% → 5–10%
- ChangedHSU, GEOFFREY, CHE-CHANG · ownership 5–10% → 10–25%
- ChangedRizzo, Matthew, Scott · ownership Less than 5% → 5–10%
- ChangedSTEVENS, CHARLES, SCOTLAND · ownership Less than 5% → 5–10%
- ChangedThompson, Peter, Armstrong · ownership Less than 5% → 5–10%
- AddedASHIYA, MONA · MEMBER · Less than 5% · control person
- No longer listedSILVERSTEIN, JONATHAN, TODD · MEMBER · 10–25% · control person · listed since Jan 2005
- AddedRizzo, Matthew, Scott · MEMBER · Less than 5% · control person
- AddedThompson, Peter, Armstrong · MEMBER · Less than 5% · control person
- AddedBONITA, DAVID, PAUL · MEMBER · Less than 5% · control person
- No longer listedSOTIRIOU, EVAN, DEAN · CHIEF FINANCIAL OFFICER · Less than 5% · control person · listed since Oct 2011
- AddedBLOCK III, SAM · CHIEF FINANCIAL OFFICER · Less than 5% · control person
- ChangedHSU, GEOFFREY, CHE-CHANG · ownership 10–25% → 5–10%
- ChangedSTEVENS, CHARLES, SCOTLAND · title EXECUTIVE OFFICER → MEMBER
- AddedSTEVENS, CHARLES, SCOTLAND · EXECUTIVE OFFICER · Less than 5% · control person
- No longer listedISALY, SAMUEL, DAVID · MANAGING MEMBER · 50–75% · control person · listed since Jan 1998
- ChangedBORHO, SVEN, HEINZ · ownership 10–25% → 25–50%
- ChangedGORDON, CARL, LEE · ownership 10–25% → 25–50%
- ChangedHSU, GEOFFREY, CHE-CHANG · ownership Less than 5% → 10–25%
- ChangedNEILD, WILLIAM, CARTER · ownership Less than 5% → 10–25%
- ChangedSILVERSTEIN, JONATHAN, TODD · ownership 5–10% → 10–25%
- AddedCOON, DOUGLAS, W. · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ChangedCOOPER, ALEXANDER, MATTHEW · title GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER → GENERAL COUNSEL
- No longer listedSHEFFERY, MICHAEL, BART · MEMBER · 5–10% · control person · listed since Jan 1998
- ListedBORHO, SVEN, HEINZ · MEMBER · 10–25% · control person
- ListedCOOPER, ALEXANDER, MATTHEW · GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ListedGORDON, CARL, LEE · MEMBER · 10–25% · control person
- ListedHSU, GEOFFREY, CHE-CHANG · MEMBER · Less than 5% · control person
- ListedISALY, SAMUEL, DAVID · MANAGING MEMBER · 50–75% · control person
- ListedNEILD, WILLIAM, CARTER · MEMBER · Less than 5% · control person
- ListedSHEFFERY, MICHAEL, BART · MEMBER · 5–10% · control person
- ListedSILVERSTEIN, JONATHAN, TODD · MEMBER · 5–10% · control person
- ListedSOTIRIOU, EVAN, DEAN · CHIEF FINANCIAL OFFICER · Less than 5% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- EDGEWISE THERAPEUTICS INC$141.7M +29.0%
- ELI LILLY & CO$91.5M +42.0%
- MBX BIOSCIENCES INC$80.7M +74.3%
- COGENT BIOSCIENCES INC$52.7M +424.8%
- UNIQURE NV$48.3M +138.4%
Top Trims
- BOSTON SCIENTIFIC CORP-$86.2M -57.7%
- COMPASS THERAPEUTICS INC-$47.2M -58.6%
- DISC MEDICINE INC-$42.1M -61.7%
- ALNYLAM PHARMACEUTICALS INC-$34.3M -87.0%
- INTUITIVE SURGICAL INC-$33.4M -34.7%
New Positions
- UNITEDHEALTH GROUP INC$67.0M
- ASCENDIS PHARMA A/S$65.2M
- HUMANA INC$65.2M
- ODYSSEY THERAPEUTICS INC$56.2M
- ARCUTIS BIOTHERAPEUTICS INC$53.5M
Exited Positions
- MYRIAD GENETICS INC$122.9M
- PFIZER INC$54.7M
- DANAHER CORP DEL$50.4M
- AVITA MEDICAL INC$42.5M
- ASCENDIS PHARMA A/S$41.6M
ORBIMED ADVISORS LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $630.5M | 11.68% | 15,518,492 | SH |
| 2 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $343.9M | 6.37% | 6,776,632 | SH |
| 3 | ELI LILLY & CO | LLY | 532457108 | $309.3M | 5.73% | 257,900 | SH |
| 4 | MBX BIOSCIENCES INC | MBX | 55287L101 | $189.3M | 3.51% | 3,428,736 | SH |
| 5 | SINOVAC BIOTECH LTD | SVA | P8696W104 | $184.5M | 3.42% | 2,718,735 | SH |
| 6 | ASTRAZENECA PLC | AZN | G0593M107 | $171.1M | 3.17% | 915,700 | SH |
| 7 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $118.6M | 2.20% | 2,209,400 | SH |
| 8 | SIONNA THERAPEUTICS INC | SION | 829401108 | $112.4M | 2.08% | 2,555,877 | SH |
| 9 | CORVUS PHARMACEUTICALS INC | CRVS | 221015100 | $107.0M | 1.98% | 7,165,006 | SH |
| 10 | ARRIVENT BIOPHARMA INC | AVBP | 04272N102 | $105.2M | 1.95% | 3,027,328 | SH |
| 11 | GUARDANT HEALTH INC | GH | 40131M109 | $87.6M | 1.62% | 583,700 | SH |
| 12 | ARGENX SE | ARGX | 04016X101 | $86.2M | 1.60% | 92,880 | SH |
| 13 | MERCK & CO INC | MRK | 58933Y105 | $85.2M | 1.58% | 663,400 | SH |
| 14 | UNIQURE NV | QURE | N90064101 | $83.3M | 1.54% | 1,807,486 | SH |
| 15 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $77.0M | 1.43% | 230,100 | SH |
| 16 | EDWARDS LIFESCIENCES CORP | EW | 28176E108 | $75.5M | 1.40% | 834,900 | SH |
| 17 | PRELUDE THERAPEUTICS INC | PRLD | 74065P101 | $73.2M | 1.36% | 13,724,571 | SH |
| 18 | ABIVAX SA | ABVX | 00370M103 | $72.8M | 1.35% | 546,522 | SH |
| 19 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $71.9M | 1.33% | 3,235,684 | SH |
| 20 | NATERA INC | NTRA | 632307104 | $71.1M | 1.32% | 262,000 | SH |
| 21 | CG ONCOLOGY INC | CGON | 156944100 | $69.1M | 1.28% | 972,800 | SH |
| 22 | UNITEDHEALTH GROUP INC | UNH | 91324P102 | $67.0M | 1.24% | 161,100 | SH |
| 23 | ARS PHARMACEUTICALS INC | SPRY | 82835W108 | $66.4M | 1.23% | 8,288,510 | SH |
| 24 | ASCENDIS PHARMA A/S | ASND | K08588103 | $65.2M | 1.21% | 244,456 | SH |
| 25 | HUMANA INC | HUM | 444859102 | $65.2M | 1.21% | 164,100 | SH |
| 26 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $65.1M | 1.21% | 1,681,300 | SH |
| 27 | BOSTON SCIENTIFIC CORP | BSX | 101137107 | $63.3M | 1.17% | 1,483,200 | SH |
| 28 | INTUITIVE SURGICAL INC | ISRG | 46120E602 | $62.8M | 1.16% | 157,900 | SH |
| 29 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $56.9M | 1.05% | 2,110,300 | SH |
| 30 | ODYSSEY THERAPEUTICS INC | ODTX | 67613T104 | $56.2M | 1.04% | 3,001,198 | SH |
| 31 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $53.9M | 1.00% | 892,471 | SH |
| 32 | ARCUTIS BIOTHERAPEUTICS INC | ARQT | 03969K108 | $53.5M | 0.99% | 2,042,000 | SH |
| 33 | BRISTOL-MYERS SQUIBB CO | BMY | 110122108 | $53.3M | 0.99% | 925,000 | SH |
| 34 | Q32 BIO INC | QTTB | 746964105 | $52.6M | 0.97% | 4,127,987 | SH |
| 35 | STRYKER CORPORATION | SYK | 863667101 | $50.1M | 0.93% | 159,100 | SH |
| 36 | CARIS LIFE SCIENCES INC | CAI | 142152107 | $50.0M | 0.93% | 2,806,811 | SH |
| 37 | SPDR SERIES TRUST Put | XBI | 78464A870 | $47.5M | 0.88% | 300,000 | SH |
| 38 | THERMO FISHER SCIENTIFIC INC | TMO | 883556102 | $45.5M | 0.84% | 90,700 | SH |
| 39 | PALVELLA THERAPEUTICS INC NE | PVLA | 697947109 | $44.7M | 0.83% | 292,360 | SH |
| 40 | ELEVANCE HEALTH INC FORMERLY | ELV | 036752103 | $44.4M | 0.82% | 114,700 | SH |
| 41 | SHATTUCK LABS INC | STTK | 82024L103 | $43.8M | 0.81% | 6,306,127 | SH |
| 42 | UPSTREAM BIO INC | UPB | 91678A107 | $39.4M | 0.73% | 5,693,589 | SH |
| 43 | CRINETICS PHARMACEUTICALS IN | CRNX | 22663K107 | $37.4M | 0.69% | 999,000 | SH |
| 44 | RHYTHM PHARMACEUTICALS INC | RYTM | 76243J105 | $35.9M | 0.66% | 322,900 | SH |
| 45 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $33.7M | 0.62% | 1,542,000 | SH |
| 46 | FORTE BIOSCIENCES INC | FBRX | 34962G208 | $33.5M | 0.62% | 1,577,705 | SH |
| 47 | COMPASS THERAPEUTICS INC | CMPX | 20454B104 | $33.3M | 0.62% | 15,219,994 | SH |
| 48 | NEKTAR THERAPEUTICS | NKTR | 640268306 | $32.5M | 0.60% | 465,346 | SH |
| 49 | KRYSTAL BIOTECH INC | KRYS | 501147102 | $30.9M | 0.57% | 83,200 | SH |
| 50 | PRELUDE THERAPEUTICS INC | WSDDF | 000000000 | $30.3M | 0.56% | 5,680,186 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $5.40B | 129 | 0001172661-26-003740 |
| 2026-03-31 | 2026-05-15 | $5.05B | 114 | 0001172661-26-002369 |
| 2025-12-31 | 2026-02-17 | $4.90B | 108 | 0001172661-26-001119 |
| 2025-09-30 | 2025-11-14 | $4.26B | 110 | 0001172661-25-005047 |
54TH FLOOR
NEW YORK, NY 10022